https://www.fiercebiotech.com/biotech/servier-pays-70m-polish-black-diamonds-deprioritized-solid-tumor-prospect
Servier pays $70M for Black Diamond's deprioritized cancer drug
Mar 19, 2025 - After cutting support for BDTX-4933, the biotech has licensed the RAF inhibitor to Servier for $70 million upfront and $710 million in milestones.
black diamondservierpayscancerdrug